Nippon India Pharma Fund Direct Growth
Equity
Direct
Sector - Healthcare
NAV as on 13-03-2025
₹ 515.24
1D
Inception Returns
17.8%
/yr
About Nippon India Pharma Fund Direct Growth
Nippon India Pharma Fund Direct Growth is an equity fund. This fund was started on 1 January, 2013. The fund is managed by Kinjal Desai, Sailesh Raj Bhan. The fund could potentially beat inflation in the long-run.
Key Parameters
- Nippon India Pharma Fund Direct Growth has ₹7637 Cr worth of assets under management (AUM) as on Jan 2025 and is more than category average.
- The fund has an expense ratio 0.9.
Returns
Nippon India Pharma Fund Direct Growth has given a CAGR return of 17.82% since inception. Over the last 1, 3 and 5 years the fund has given a CAGR return of 12.49%, 18.45% and 26.94% respectively.
Holdings
Nippon India Pharma Fund Direct Growth has allocated its funds majorly in Health, Cash Equivalent. Its top holdings are Sun Pharmaceuticals Industries Ltd, Divi's Laboratories Ltd, Lupin Ltd, Cipla Ltd, Dr Reddy's Laboratories Ltd
Taxation
As it is a sector - healthcare mutual fund the taxation is as follows:For short term (less than a year) capital gains will be taxed at 20%For long term (more than 1 year) capital gains will be taxed at 12.5% without indexation benefitDividends will always be taxed at slab rate. Long term gains upto Rs 1 lakh are exempt capital gains tax.
Investment objective of Nippon India Pharma Fund Direct Growth
The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.
Minimum Investment and lockin period
Minimum investment for lump sum payment is INR 5000.00 and for SIP is INR 100.00. Nippon India Pharma Fund Direct Growth has no lock in period.
Historical NAV & Returns
Absolute
▲
▼
7209 people have invested ₹ 3.4Cr in Nippon India Pharma Fund Direct Growth in the last three months
INDmoney Rank for Nippon India Pharma Fund Direct Growth
Powered by IND quant engine
IND ranking is not available for this fund.
Among most bought funds within the category
Larger AUM within category
Beats FD returns for both 3Y & 5Y duration
No bad points found for this fund.
Nippon India Pharma Fund Direct Growth Overview
| Expense ratio | 0.91% |
Benchmark | S&P BSE Healthcare PR |
| AUM | ₹7637 Cr |
| Inception Date | 1 January, 2013 |
| Min Lumpsum/SIP | ₹5000/₹100 |
Exit Load | 1.0% |
| Lock In | No Lock-in |
TurnOver | 16.09% |
| STCG | Selling mutual fund before 1 year, returns taxed at 20%. |
| LTCG | After 1 year, 12.5% tax on returns over ₹1.25 lakh/year. |
| Risk |   Very High Risk |
Trailing Returns
as on (13-Mar-25)
Fund Distribution
as on (31-Jan-25)
Large cap
38.5%
Mid cap
33.7%
Small cap
26.7%
Sector Allocation
Health
100%
All changes are between Nov'24 and Jan'25
- AUM of the fund stands at 7.6K Cr as of Feb'25
- AUM decreased by 523.7 Cr between Feb'25 and Jan'25
Top Stocks bought last month
Ipca Laboratories Ltd's allocation increased from 0.45% to 1.1%
Narayana Hrudayalaya Ltd's allocation increased from 2.14% to 2.55%
Sai Life Sciences Ltd's allocation increased from 0.53% to 0.88%
Top Stocks sold last month
Divi's Laboratories Ltd's allocation decreased from 9.24 % to 9.23 %
Lupin Ltd's allocation decreased from 8.47 % to 8.16 %
Medplus Health Services Ltd's allocation decreased from 3.32 % to 3.16 %
Mid Cap allocation has gone up from 28% to 33.7%
Large Cap allocation has gone down from 46.4% to 38.5%
Small Cap allocation has gone up from 20.5% to 26.7%
Cash allocation has gone down from 1.4% to 1.1%
Top Sector in February was Health
Feb'25
Health
100%
Jan'25
Health
100%
See all
Top Growth Drivers | 1M Return |
|---|---|
 Narayana Hrudayalaya Ltd | 16.2% |
 Glaxosmithkline Pharmaceuticals Ltd | 13.6% |
 Abbott India Ltd | 3.6% |
Loading...
We are taking more time than usual
Kinjal Desai
Fund Manager of Nippon India Pharma Fund Direct Growth, since 25 May 2018
Top funds managed
Sailesh Raj Bhan
Fund Manager of Nippon India Pharma Fund Direct Growth, since 1 April 2005
Top funds managed
Fund House
Nippon Life India Asset Management Ltd
Total Schemes
Total AUM
₹4.25L Cr
as on 31-Jan-2025
Address
Nippon Life India Asset Management Limited,4th Floor, Tower A, Peninsula Business Park,,Ganapatrao Kadam Marg,,Lower Parel (W)
Phone
022-68087000/18602660111
Website
customercare@nipponindiaim.in
Mutual Fund Insights
In the last 5 years, ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund Direct Growth has given 29.49% return, outperforming this fund by 2.55% per annum.
Over the last 1 year, this fund has decreased expense ratio by 3.2% moving from 0.94 to 0.91.
In the last 3 years, SBI Healthcare Opportunities Fund Direct Growth has given 23.02% return, outperforming this fund by 4.56% per annum.
Over the last 3 months, this fund has experienced a 11.6% drop in AUM moving from 8.63K Cr to 7.63K Cr.
In the last 1 year, HDFC Pharma and Healthcare Fund Direct Growth has given 29.68% return, outperforming this fund by 17.19%.
This fund has one of the lowest expense ratio in the category (sector - healthcare). Its expense ratio is 0.91% which is lower than the category average expense ratio of 1.4%.
Nippon India Pharma Fund Direct Growth Highlights
Very High Risk
Investors understand that their principal will be at Very High Risk
About the fund
This fund has delivered an average annual returns of 17.82% since inception which is more than its category average return of 15.39%
Fund Allocations
This fund has an allocation of 98.89% in Equity, 0% in Debt and 1.11% in Cash related instruments
AUM size ₹7637 Cr
This fund has AUM of ₹7637 Cr which is more than its category average of ₹ 1725 Cr
Expense Ratio 0.91%
This fund has an expense ratio of 0.91% which is less than its category average expense ratio of 1.43%
Frequently Asked Questions for Nippon India Pharma Fund Direct Growth
The current NAV of Nippon India Pharma Fund Direct Growth is ₹515.24 as on 13-Mar-2025.
Existing (Absolute + CAGR) as on 13-Mar-2025.
Nippon India Pharma Fund Direct Growth | Absolute Returns | CAGR Returns |
1 Month Returns | -2.24% | -2.24% |
6 Month Returns | -11.73% | -11.73% |
1 Year Returns | 12.49% | 12.49% |
3 Years Returns | 66.2% | 18.45% |
5 Years Returns | 229.6% | 26.94% |
With INDmoney, the process of investing is very simple and involves zero commission.
- Click Buy on the fund name.
- Input the amount you are looking to invest.
- Select Lump Sum or SIP (Weekly, Monthly or Quarterly).
- Select your bank account and proceed with Payment.
0.91% as on February 2025
₹7637 Cr as on February 2025
Sun Pharmaceuticals Industries Ltd(13.68%), Divi's Laboratories Ltd(9.32%), Lupin Ltd(7.73%), Cipla Ltd(5.9%), Dr Reddy's Laboratories Ltd(5.35%) as on February 2025
The alpha ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Alpha 1 Year | Alpha 3 Years | Alpha 5 Years |
Nippon India Pharma Fund Direct Growth | -3 | 0.8 | 1.78 |
As on February 2025
The alpha for Nippon India Pharma Fund Direct Growth is calculated against S&P BSE Healthcare PR. Higher alpha indicates that this fund has generated extra returns compared to the benchmark index. An alpha of 1.0 means the fund has outperformed its benchmark index by 1%.
The Beta ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Beta 1 Year | Beta 3 Years | Beta 5 Years |
Nippon India Pharma Fund Direct Growth | 0.88 | 0.91 | 0.93 |
As on February 2025
The Beta for Nippon India Pharma Fund Direct Growth is calculated with S&P BSE Healthcare PR. Beta tells the volatility of the mutual fund relative to its benchmark. If the beta of a mutual fund is more than 1, then the mutual fund is more volatile than its benchmark. If beta is less than 1, then the mutual fund is less volatile than the benchmark.
The sharpe ratio for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Sharpe Ratio 1 Year | Sharpe Ratio 3 Years | Sharpe Ratio 5 Years |
Nippon India Pharma Fund Direct Growth | 0.03 | 0.77 | 0.97 |
As on February 2025
The sharpe ratio for Nippon India Pharma Fund Direct Growth is calculated with S&P BSE Healthcare PR. Sharpe ratio tells risk-adjusted-returns of the mutual fund. The higher a fund's Sharpe ratio, the better a fund's returns have been relative to the risk it has taken on.
The standard deviation for the Nippon India Pharma Fund Direct Growth for various period is as follows:
Fund Name | Standard Deviation 1 Year | Standard Deviation 3 Years | Standard Deviation 5 Years |
Nippon India Pharma Fund Direct Growth | 17.05 | 15.64 | 19.44 |
As on February 2025
Standard deviation tells the volatility of the returns of the mutual fund. The higher a fund's Standard deviation, the higher the volatility of the fund's returns.
Sortino ratio is 1.31 as on February 2025. Sortino ratio tells the downside risk-adjusted-returns of the mutual fund.
Kinjal Desai, Sailesh Raj Bhan are the fund managers of Nippon India Pharma Fund Direct Growth
The Exit load of Nippon India Pharma Fund Direct Growth is 1%